News
Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease
Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It is estimated that a 60-year-old patient with T2DM loses an average of 6–7 years of life compared to a person of the same age without T2DM. What impact does modern pharmacotherapy have on this adverse balance?
Monitoring of Joint Health is an Important Part of Hemophilia Care
Joint health has become a key aspect of the quality of life for people with hemophilia. The…
Effect of Etanercept on Structural Changes in the Sacroiliac Joint in Patients with Early Axial Spondyloarthritis
Currently, there is limited evidence regarding the effect of tumor necrosis factor inhibitors on…
Alleviation of Asthma and Chronic Sinusitis Symptoms in Patients with Atopic Dermatitis Thanks to Dupilumab
An analysis of results in adult patients with moderate to severe atopic dermatitis, who also had…
Effect of Telmisartan and Losartan on Bone Turnover Markers in Patients with Newly Diagnosed Stage I Hypertension
Telmisartan, an AT1 receptor blocker for angiotensin II and partial agonist of the PPAR-γ receptor,…
The Anti-inflammatory and Renoprotective Effect of Candesartan May Be Independent of the AT1 Receptor
Candesartan belongs to the blockers of AT1 receptors (AT1R) for angiotensin II coupled with G…
Programmed Cell Death as a Therapeutic Target in Chronic Lymphocytic Leukemia
One of the key steps in malignant transformation is the disruption of apoptosis. Tumor cells…
Teriflunomide vs. Dimethyl Fumarate in Real Practice: We Know the Winner! Will It Surprise You?
Teriflunomide and dimethyl fumarate are disease-modifying drugs (DMDs) used in the treatment of multiple...
MS, NMOSD and COVID-19: What Did a Year of Pandemic in Czechia Mean for Our Patients and Which Risk Factors Were Confirmed?
What is the incidence and course of COVID-19 in patients with multiple sclerosis (MS) and diseases from...
Intracranial Activity of Lorlatinib in Patients with Metastatic ALK-Positive NSCLC
Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor with significant…